Literature DB >> 20724351

Elevated levels of human beta-defensin 2 and human neutrophil peptides in systemic lupus erythematosus.

S Vordenbäumen1, R Fischer-Betz, D Timm, O Sander, G Chehab, J Richter, E Bleck, M Schneider.   

Abstract

OBJECTIVE: Defensins are immunomodulatory peptides and components of the innate immune response. They have been shown to be modulated in various disease states and in response to inflammatory stimuli. Recently, alpha-defensins have been implicated in the pathogenesis of autoimmune diseases. In order to explore whether these defensins may have a role in the pathogenesis of systemic lupus erythematosus (SLE), we sought to determine whether altered expression can be found in SLE patients.
MATERIAL AND METHODS: Serum and EDTA-blood of 50 SLE patients who fulfilled the American College of Rheumatology (ACR) criteria (aged 41.4 ± 13.3 years) and 28 age- and sex-matched healthy controls were collected. Real-time polymerase chain reaction with gene-specific primers for human neutrophil peptides (HNPs), human beta-defensin 2 and 3 (hBD2, 3) in isolated polymorphonuclear cells and enzyme-linked immunosorbent assay (ELISA) in serum samples were performed. Results of SLE patients were compared with the control group and correlated to routine laboratory parameters, clinical data and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
RESULTS: SLE patients were predominantly female (90%) with a mean SLEDAI of 5.7 ± 6.1. In sera, patients displayed higher amounts of hBD2 and HNPs when compared with healthy controls. Furthermore, hBD2 correlated with levels of anti-dsDNA antibodies, erythrocyte count and the SLEDAI. Elevated values were observed in patients with myositis (n = 4). Serum HNPs on the other hand correlated with the neutrophil count and was elevated in patients with a rash (n = 7). Lupus patients suffering from transverse myelitis (n = 3) had raised serum-values of both HNPs and hBD2. While no mRNA of hBD2 or hBD3 was detected in polymorphonuclear cells, HNP mRNA was found in both healthy controls and patients without significant difference. Lupus nephritis and rash were associated with higher amounts of HNP mRNA, and the relative amount of copies correlated positively with the SLEDAI and negatively with C3 measurements.
CONCLUSIONS: Serum levels of hBD2 and HNPs are elevated in SLE. The correlations of hBD2 and HNPs to established disease activity parameters and distinct clinical situations suggest that innate immune mechanisms are activated. Defensins may be involved in SLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724351     DOI: 10.1177/0961203310377089

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  20 in total

Review 1.  Neutrophils in the pathogenesis and manifestations of SLE.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

2.  Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.

Authors:  Eneida Villanueva; Srilakshmi Yalavarthi; Celine C Berthier; Jeffrey B Hodgin; Ritika Khandpur; Andrew M Lin; Cory J Rubin; Wenpu Zhao; Stephen H Olsen; Matthew Klinker; David Shealy; Michael F Denny; Joel Plumas; Laurence Chaperot; Matthias Kretzler; Allen T Bruce; Mariana J Kaplan
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

3.  Copy Number Variation within Human β-Defensin Gene Cluster Influences Progression to AIDS in the Multicenter AIDS Cohort Study.

Authors:  Rajeev K Mehlotra; Jean-Eudes Dazard; Bangan John; Peter A Zimmerman; Aaron Weinberg; Richard J Jurevic
Journal:  J AIDS Clin Res       Date:  2012

4.  A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy.

Authors:  Xue-Qing Yu; Ming Li; Hong Zhang; Hui-Qi Low; Xin Wei; Jin-Quan Wang; Liang-Dan Sun; Kar-Seng Sim; Yi Li; Jia-Nee Foo; Wei Wang; Zhi-Jian Li; Xian-Yong Yin; Xue-Qing Tang; Li Fan; Jian Chen; Rong-Shan Li; Jian-Xin Wan; Zhang-Suo Liu; Tan-Qi Lou; Li Zhu; Xiao-Jun Huang; Xue-Jun Zhang; Zhi-Hong Liu; Jian-Jun Liu
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

5.  Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener's granulomatosis.

Authors:  Stefan Vordenbäumen; Daniel Timm; Ellen Bleck; Jutta Richter; Rebecca Fischer-Betz; Gamal Chehab; Oliver Sander; Matthias Schneider
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

6.  β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation.

Authors:  Poonam Tewary; Gonzalo de la Rosa; Neeraj Sharma; Luis G Rodriguez; Sergey G Tarasov; O M Zack Howard; Hidekazu Shirota; Folkert Steinhagen; Dennis M Klinman; De Yang; Joost J Oppenheim
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

7.  Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus.

Authors:  Jason S Knight; Wenpu Zhao; Wei Luo; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Jeffrey B Hodgin; Daniel T Eitzman; Paul R Thompson; Mariana J Kaplan
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

Review 8.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

9.  Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.

Authors:  Jison Hong; David J Maron; Tsuyoshi Shirai; Cornelia M Weyand
Journal:  Int J Clin Rheumtol       Date:  2015-10

10.  Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.

Authors:  Jeffrey P Meisch; Michiko Nishimura; Ryan M Vogel; Hannah C Sung; Beth A Bednarchik; Santosh K Ghosh; Pingfu Fu; Thomas McCormick; Aaron Weinberg; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.